Abbott launches the FDA-cleared IonicRF Generator, designed to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system.
The radiofrequency ablation device, which uses heat to target specific nerves and block pain signals from reaching the brain, is currently approved in the United States and Europe, according to a media release from Abbott.
“Every patient is different and the source of their pain is unique, making it extremely important to have multiple options available, so treatment can be tailored to individual circumstances.
“Abbott’s IonicRF is an advanced device platform that targets specific nerves to block pain signals from reaching the brain. One of the most promising aspects of the therapy is its effectiveness in targeting pain in several discrete areas of the body.”
— Jason E. Pope, MD, Evolve Restorative Center, Santa Rosa, Calif
Radiofrequency ablation uses an electric current to heat up a small area of nerve tissue to stop it from sending pain signals, the release continues.
“Most people who are candidates for radiofrequency ablation have tried other therapies, such as medications and injections, with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication.”
— Keith Boettiger, vice president, Neuromodulation, Abbott
[Source(s): Abbott, PR Newswire]